Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management
2014年4月24日 更新者：Linda Gonder-Frederick、University of Virginia
This study combines data collection and simulation-based education, and it will enroll up to 36 adults with T1DM who already have experience with insulin pump therapy and some experience with a continuous glucose monitor (CGM).
The study will first track participants for of a 3-day CGM-training period.
The training period will be followed by a 1-week CGM monitoring and CGM data collection period.
Following the 1-week CGM monitoring-only portion of the study, participants will begin the education intervention component of the study, referred to as Insight-Based Online Learning Using Simulation and Education for Diabetes (iBOLUSED).
The education intervention component is 4 weeks in length.
The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data.
During the first week (and for up to 2 weeks) of the intervention, participants will view glycemic outcome data that represents the participant's hypo- and hyperglycemic risk throughout the day, based on the CGM data collected during the CGM monitoring period.
In the next 2 weeks of the intervention, participants will have an opportunity to interact with the internet-based system using a simulation-based tool designed to provide insight to the participant regarding the different effects of modifications to insulin therapy.
Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system.
Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness.
Participants will also upload data from the CGM via the Dexcom Data Manager 3 (DM3) software or the Dexcom Studio Software.
Two assessments, one prior to the intervention period and one following the intervention, will be administered to gather relevant psychobehavioral information.
Focus group sessions will be conducted at the end of the study, which will allow for the collection of information regarding the effectiveness of the Internet intervention and will provide insight for the design of future studies.
Parallel recording of CGM, insulin, and behavioral data, as well as psychometric instruments, will produce a rich synchronized data set for each person that will facilitate the development of personalized behavioral profiles that will be employed to provide individualized feedback to educate participants.
In particular, this study tests the use of collected diary data to educate participants by describing glucose profile information and presenting relevant data regarding: (1) hypo- and hyperglycemia risk zones throughout the day, (2) insulin meal bolus information and associated glycemic outcome indices, and (3) basal rate information with associated glycemic outcome indices.
調査の概要
詳細な説明
Development of an insulin delivery educational tool in T1DM requires fundamental behavioral and physiology studies, as well as translational modeling and engineering development.
In order to be successful, Closed Loop Control (CLC) in T1DM must adapt to individual physiologic characteristics and to the behavioral profile of each person.
Here, we have laid the foundation by testing an educational tool that aims at providing feedback to patients with the goal of optimizing patient's glucose control under conventional insulin therapy.
This educational tool is based on collecting data from patients that are processed by algorithms giving insight into the relationship between glucose control and psychobehavioral characteristics of the individual.
This information will eventually inform a CLC system, which will be initialized for each individual based on relevant behavioral and physiologic characteristics, and will include algorithmic observers of patients' behavior and metabolic state.
研究の種類
観察的
入学 (実際)
15
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22904
- University of Virginia Center for Diabetes Technology
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
21年～65年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
サンプリング方法
確率サンプル
調査対象母集団
Type 1 Diabetes Mellitus study subjects that are currently identified in the Center for Diabetes Technology recruitment database.
Subject be currently wearing an insulin pump for at least 6 months and must have worn a continuous glucose monitor for at least 6 weeks during the past 2 years.
説明
Inclusion Criteria:
For this pilot trial, recruitment will ONLY occur through UVa's IRB-HSR #14263 Recruitment Database.
Inclusion criteria for subject to enroll:
- T1DM (as defined by the American Diabetes Association criteria or judgment of a physician) for at least 2 years prior to the enrollment in the study
- Age 21-65.
- Use of an insulin pump to treat their diabetes for at least 6 months.
- Use of a CGM for at least a 6 week period in the past 2 years.
- Has the ability to use a computer that is capable of running the Dexcom Data Manager 3 (DM3) software daily.
- Has regular access to the Internet.
- Has an identified healthcare provider who can provide advice about diabetes care.
- Actively using a bolus calculator function with the current insulin pump with pre-defined parameters for glucose goal, carbohydrate ratio, and insulin sensitivity factor.
- Willingness to participate in the study for 11 weeks wearing a DexCom CGM for the duration of the study and perform daily journaling of BG, pump activity, meals, physical activity, stress level and menstrual cycle for 3 weeks during the study intervention period.
- Willingness to do extra fingersticks when CGM alarms at low or high end (<70 mg/dl or >300 mg/dl),
- Willingness to come to Center for Diabetes Technology on at least two occasions to obtain and return supplies.
- Willingness to avoid consumption of acetaminophen-containing products for the duration of the study.
- Demonstration of proper mental status and cognition for completion of the study.
- Has the ability to contact their own personal diabetes care team to have clinical questions answered about changes to diabetes treatment.
Exclusion Criteria:
- Individuals with cognitive impairment that prevents understanding either consent form or intervention content
- Active renal dialysis
- Psychiatric disorders that would interfere with study tasks (e.g., substance abuse)
- History of a systemic deep tissue infection with methicillin-resistant staph aureus or Candida albicans
- Known bleeding diathesis or dyscrasia
- Pregnant or intending to get pregnant during study
- Active enrollment in another clinical trial
- Medical requirement for acetaminophen-containing products during the study period for more than 1 week
- Medical condition that would make operating a CGM or insulin pump difficult (e.g. blindness, severe arthritis, extensive scar tissue at sites where devices are inserted)
- Individuals who do not have access to their diabetes care team to have clinical questions answered about changes in their diabetes treatment.
- Need for magnetic resonance imaging (MRI)/magnetic resonance angiogram (MRA)during the study
List any restrictions on use of other drugs or treatments:
The CGM must be removed prior to Magnetic Resonance Imaging and use of acetaminophen-containing medications while using the CGM sensor may affect the performance of the device. Therefore, MRI and products containing acetaminophen will be restricted. If either is required out of medical necessity, the DexCom® will be removed and participant will have the option of repeating the involved study week. If the medical condition requires use of acetaminophen for longer than 1 week, the participant will be dropped from the study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Group A: CGM monitoring (1) vs Intervention
Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention.
The 4 week intervention period will be followed by an additional CGM monitoring period (session 2).
For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
|
The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data.
Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system.
Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness.
Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
他の名前：
|
|
Group B: CGM monitoring (2) vs Intervention
Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention.
The 4 week intervention period will be followed by an additional CGM monitoring period (session 2).
For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
|
The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data.
Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system.
Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness.
Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Accuracy of Feedback and Intervention Feasibility
時間枠：within 6 months of study conclusion
|
We will assess the ability of our intervention to provide accurate, useful data to participants that can improve quality of life and educate patients regarding glycemic outcome based on participant feedback collected in focus groups, the post-intervention psychobehavioral assessment, and based on an analysis of the accuracy of the feedback data presented to users based on the input (diary) data.
A comparison of input diary data metrics (glucose and insulin data) to output feedback (BG risk profiles, glycemic variability metrics) will allow us to quantify this accuracy.
Feasibility of the intervention will be assessed through analysis of pre- and post- assessments, and through feedback provided by subjects during the focus group sessions.
A statistician with a background in qualitative data analysis will analyze the psychobehavioral assessment and focus group data.
|
within 6 months of study conclusion
|
|
Ability of Behavioral Intervention to Improve Glycemic Outcome
時間枠：within 6 months of study conclusion
|
Measure the ability of the simulation-based feedback system intervention to assist in improving the nominal glucose profile based on a pre- and post-intervention assessment of the data. We hypothesize that, compared to the use of CGM alone, the educational system will result in: A2.1: Increased time within target range, defined as 70-140mg/dl overnight and 70-180mg/dl during the day; A2.2: Reduced risk for hypoglycemia, specifically reduction in nocturnal hypoglycemic episodes; A2.3: Reduced postprandial glucose variability and avoidance of hypoglycemia 3-4 hours after a meal; and A2.4: Acceptance of the system feedback by patients. |
within 6 months of study conclusion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Psychobehavioral Data to Inform Closed Loop Control Aggressiveness
時間枠：within 1 year of study conclusion
|
Collection of psychobehavioral data on individuals' fear of hypo- and hyperglycemia, and connecting the influence of these factors on insulin therapy self-management can facilitate the individualization of controller aggressiveness in the development of a closed-loop system. We study the ability of the psychobehavioral data to facilitate the individualization of controller aggressiveness in the development of a closed-loop system. The data that is used for this analysis are collected in through the pre- and post-intervention psychobehavioral assessments. |
within 1 year of study conclusion
|
|
Relationships Between Physiology and Behavior Transferred to In Silico Environment
時間枠：within 2 years from study conclusion
|
Collection of relevant data to establish relationships between behavior and physiology will allow to iteratively transfer, in simulation, the influence of behavioral triggers through individual physiological parameters and metabolic mechanisms, to the final element of BG fluctuation. The collected diary data will be used to establish relationships, specifically stochastic models, between behavioral events, physiology, and self-treatment. The models are developed based on the collected data and will be incorporated into the simulation environment to capture realistically physiologic response to behavior and self-treatment strategies. |
within 2 years from study conclusion
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
協力者
捜査官
- 主任研究者：Linda Gonder-Fredrick, Ph.D.、University of Virginia Center for Diabetes Technology
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2013年3月1日
一次修了 (実際)
2013年8月1日
研究の完了 (実際)
2013年8月1日
試験登録日
最初に提出
2013年1月8日
QC基準を満たした最初の提出物
2013年1月10日
最初の投稿 (見積もり)
2013年1月14日
学習記録の更新
投稿された最後の更新 (見積もり)
2014年4月28日
QC基準を満たした最後の更新が送信されました
2014年4月24日
最終確認日
2014年4月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 16226
- R01DK085623 (米国 NIH グラント/契約)
- DP3DK094331 (米国 NIH グラント/契約)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。